Gregory Russotti
Vermögen: 1 Mio $ am 31.05.2026
Vermögen: 1 Mio $ am 31.05.2026
Gregory Russotti is currently an Advisor at Dynamk Capital LLC and Chief Technology & Manufacturing Officer at Century Therapeutics, Inc. since 2023.
Formerly, Dr. Russotti was VP, Cell Therapy Development and Operations at Celgene Corp.
from 2013 to 2019.
Education includes a doctorate from Rutgers State University of New Jersey conferred in 1996, and undergraduate and graduate degrees from Rensselaer Polytechnic Institute conferred in 1988 and 1990, respectively.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 12.06.2026 | 605.092 ( 0,34 % ) | 1 Mio $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| CENTURY THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2020 |
Dynamk Capital LLC
Dynamk Capital LLC Investment ManagersFinance Dynamk Capital invests in companies located in the United States. The firm focuses on the life sciences sector. It participates in early-stage transactions. | Berater | - |
| Unternehmen | Position | Ende |
|---|---|---|
| CELGENE | Corporate Officer/Principal | 31.12.2019 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
Rutgers State University of New Jersey
Rutgers State University of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rensselaer Polytechnic Institute
Rensselaer Polytechnic Institute Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dynamk Capital LLC
Dynamk Capital LLC Investment ManagersFinance Dynamk Capital invests in companies located in the United States. The firm focuses on the life sciences sector. It participates in early-stage transactions. | Finance |
Century Therapeutics, Inc.
Century Therapeutics, Inc. BiotechnologyHealth Technology Develops novel allogeneic living drugs for oncology that overcome the limitations of first-generation cell therapies | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen